As part of future research, these results require validation in multi-centre cohorts of breast cancer patients to determine the clinical utility of measuring calpain-9 expression as an indicator of response to endocrine therapy or in those patients with an intermediate NPI value. This evidence concerns the gene CAPN9 and breast cancer.